Lyme Disease Testing Market Size

Lyme Disease Testing Market Size

The global lyme disease testing market size was valued at USD 6.7 billion in 2024 and is expected to exhibit growth at a CAGR of 5.7% from 2025 to 2034. The market is driven by several factors that collectively enhance its growth potential. First, the increasing prevalence of Lyme disease, particularly in endemic regions like North America and parts of Europe, significantly boosts the demand for diagnostic tests.

The Centers for Disease Control and Prevention (CDC) 2024, estimates that approximately 476,000 Lyme disease cases are diagnosed annually in the U.S., underscoring the need for robust diagnostic solutions?. Technological advancements in diagnostic methods are another critical driver. The development of highly sensitive and specific technologies, such as molecular diagnostics (e.g., PCR) and next-generation serological assays (e.g., ELISA), enables early and accurate detection, even in asymptomatic patients.
 

Moreover, point-of-care (POC) tests and at-home testing kits are gaining traction, offering convenient and rapid diagnostic options?. Rising awareness about the long-term complications of untreated Lyme disease, such as chronic neurological and musculoskeletal issues, is prompting early testing and treatment. Public health campaigns by governments and non-profit organizations have significantly contributed to this awareness?. Regulatory support and funding for research into tick-borne diseases are also spurring market growth.
 

Lyme disease testing involves diagnostic procedures to detect Borrelia burgdorferi, the bacteria responsible for Lyme disease, primarily transmitted through tick bites. Testing methods include serological tests like ELISA and Western blot, molecular diagnostics like PCR, and antigen-based tests. These tests analyze samples such as blood, cerebrospinal fluid (CSF), or urine to identify infection stages, enabling timely and accurate treatment. Early detection is vital to prevent severe complications.